Here's why I like Catapult Group International Ltd shares

Catapult Group International Ltd (ASX:CAT) reported another record sales result during the December quarter.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Catapult Group International Ltd (ASX: CAT) continued its impressive run in the three-months ended 31 December 2015, reporting record unit sales which were 66% higher than the prior corresponding period.

So What: Most sports fans are likely familiar with what Catapult does. The company provides the software and hardware used to track the performance of athletes on and off the field. For many teams and individuals, it has become a critical component in the lead-up to game day and shows where the athletes can improve, and whether they are at risk of injury.

Indeed, Catapult has agreements with NFL and NBA teams, field and ice hockey teams, as well as teams in the English Premier League. It also signed new league-wide agreements with the Australian Rugby Union and Australian Football League (AFL) during the period.

The company said it had sold 2,000 new units during the quarter, surpassing the previous record of 1,854 units in the fourth quarter of financial year 2015 (Q4 FY15).

It now has a total of 5,753 units under subscription (representing 15% growth on the prior quarter) with annualised run rate (ARR) from subscription revenue of $9.1 million. Catapult's management said this sales result was consistent with the FY16 outlook which it provided at the annual general meeting (AGM) in November 2015. At the time, it lifted its guidance to a minimum of 8,000 units, delivering $24.5 million in total contract value (TCV).

Now What: Catapult Group is recording some very impressive growth, but sometimes the best indications of the future of the product can come from the customers themselves. In the presentation for the group's AGM, Catapult provided some reviews from teams around the world which I believe highlight the company's potential.

Firstly though, I'll note that I do not own shares in Catapult Group, and cannot buy for at least two days after I've written about it based on The Motley Fool's strict trading rules. However, it is certainly on my watchlist. Here's one review from Roger Marandino, Strength and Conditioning coach at Indianapolis Colts:

"It's the biggest breakthrough I have experienced in my life. Football is an extreme sport and our goal is to have players working at a very high level without damaging them. We want to balance work and injury prevention."

And this from The Golden State Warriors:

"The Golden State Warriors (NBA) finished with the fewest minutes lost due to injury in the NBA. And in the postseason, they finished as champions. Technology and data analysis are pillars of the Warriors' front office."

Of course, investors should always keep in mind that reviews provided by the company itself will almost always give them a good wrap, and others may feel differently about the products. But those reviews are certainly encouraging.

Investors should also be aware of the potential for competition risk, especially from bigger players such as Adidas or Nike, which could hinder Catapult's growth potential. Catapult's shares are currently trading for $2.08 and have risen 285% over the last 12 months. That compares to a 9% fall for the benchmark ALL ORDINARIES (Index: ^AXAO) (ASX: XAO).

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nike. Motley Fool contributor Ryan Newman has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. You can follow Ryan on Twitter @ASXvalueinvest. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »